Tempus AI has acquired Paige, a digital pathology company, in an $81.25 million deal paid mostly in common stock, enhancing Tempus’ capabilities in cancer diagnosis and precision medicine. Paige brings a dataset of nearly seven million digitized pathology slides linked with clinical and molecular data from diverse populations across 45 countries. This acquisition accelerates Tempus’ efforts to build a large oncology foundation model, including Paige’s FDA-cleared AI applications for pathology diagnostics, such as their prostate cancer test and breast cancer lymph node metastases detection algorithm. Tempus plans to integrate Paige’s technology and team to advance innovative diagnostic tools and drug discovery.